STAT1d
They agreed to cover a drug for six months — and now I have to fight for it again
Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...
BioPharma Dive21h
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...
Private Medicare plans must cover Biogen's ALS drug, US agency says
The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...
Biogen ALS drug needs to be covered by MA plans, CMS says
Medicare Advantage plans must cover Biogen’s (NASDAQ:BIIB) drug Qalsody for the treatment of ALS, according to a report. The ...
Corcept Therapeutics' ALS drug fails in mid-stage trial
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
devdiscourse19h
Healthcare Headlines: Lawsuits, Bids, and Drug Approvals Shake Industry
This summary covers key developments in health news, including Mitsubishi Pharma's bidding war, legal actions involving J&J ...
pharmaphorum3d
uniQure rockets on map to market for Huntington's therapy
Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
pharmaphorum5d
Biogen gets FDA approval for ALS drug Qalsody
The drug – branded as Qalsody – is the first therapy to be approved for a genetic form of ALS, and is also notable for being the first neurology therapeutic for which a blood biomarker has ...
The Garden Island1y
Biogen receives FDA approval for breakthrough ALS treatment: ‘Pivotal moment in ALS research’
The U.S. Food and Drug Administration on Tuesday granted approval of Qalsody for the treatment of ALS in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. Biogen’s treatment ...